Proliferative responses to altered 17β-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human breast cancer cells are dependent on endogenous expression of 17HSD type 1 and the oestradiol receptors

Endocrine-Related Cancer

Volumn 13, Issue 3, 2006, Pages 875-884

  Jansson, A ^a   Gunnarsson, C ^a   Stal O ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRADIOL RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; SMALL INTERFERING RNA; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 1; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 2; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PROTEIN DEPLETION; PROTEIN EXPRESSION;

17-HYDROXYSTEROID DEHYDROGENASES; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DNA PRIMERS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; POLYMERASE CHAIN REACTION; RECEPTORS, ESTRADIOL; S PHASE; TRANSFECTION;

EID: 33751100414     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01181     Document Type: Article

References (28)

1. Chetrite GS, Ebert C, Wright F, Philippe AC & Pasqualini JR 1999a Control of sulfatase and sulfotransferase activities by medrogestone in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology 70 39-45.
2. Chetrite GS, Ebert C, Wright F, Philippe JC & Pasqualini JR 1999b Effect of Medrogestone on 17beta-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology 68 51-56.
3. Fournier S, Brihmat F, Durand JC, Sterkers N, Martin PM, Kuttenn F & Mauvais-Jarvis P 1985 Estradiol 17 beta-hydroxysteroid dehydrogenase, a marker of breast cancer hormone dependency. Cancer Research 45 2895-2899.
4. Gunnarsson C, Olsson BM & Stal O, Southeast Sweden Breast Cancer Group 2001 Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Research 61 8448-8451.
5. Gunnarsson C, Hellqvist E & Stal O 2005 17beta-Hydroxysteroid dehydrogenases involved in local estrogen synthesis have prognostic significance in breast cancer. British Journal of Cancer 92 547-552.
6. Härkönen P, Torn S, Kurkela R, Porvari K, Pulkka A, Lindfors A, Isomaa V & Vihko P 2003 Sex hormone metabolism in prostate cancer cells during transition to an androgen-independent state. Journal of Clinical Endocrinology and Metabolism 88 705-712.
7. Ishibashi H, Suzuki T, Suzuki S, Moriya T, Kaneko C, Nakata T, Sunamori M, Handa M, Kondo T & Sasano H 2005 Estrogen inhibits cell proliferation through in situ production in human thymoma. Clinical Cancer Research 11 6495-6504.
8. Kitawaki J, Koshiba H, Ishihara H, Kusuki I, Tsukamoto K & Honjo H 2000 Progesterone induction of 17beta-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium. Journal of Clinical Endocrinology and Metabolism 85 3292-3296.
9. Koh E, Noda T, Kanaya J & Namiki M 2002 Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 5 154-159.
10. Labrie F, Luu-The V, Lin SX, Labrie C, Simard J, Breton R & Belanger A 1997 The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. Steroids 62 148-158.
11. Liu ZJ, Lee WJ & Zhu BT 2005 Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause. Cancer Research 65 5802-5811.
12. Luu-The V, Tremblay P & Labrie F 2006 Characterization of type 12 17{beta}-hydroxysteroid dehydrogenase (17{beta}-HSD12), an isoform of type 3 17{beta}-hydroxysteroid dehydrogenase responsible for oestradiol formation in women. Molecular Endocrinology 20 437-443.
13. Miettinen MM, Mustonen MV, Poutanen MH, Isomaa VV & Vihko RK 1996 Human 17 beta-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochemical Journal 314 839-845.
14. Miettinen M, Mustonen M, Poutanen M, Isomaa V, Wickman M, Soderqvist G & Vihko P 1999 17Beta-hydroxysteroid dehydrogenases in normal human mammary epithelial cells and breast tissue. Breast Cancer Research and Treatment 57 175-182.
15. Oduwole OO, Isomaa VV, Nokelainen PA, Stenback F & Vihko PT 2002 Downregulation of estrogen-metabolizing 17 beta-hydroxysteroid dehydrogenase type 2 expression correlates inversely with Ki67 proliferation marker in colon-cancer development. International Journal of Cancer 97 1-6.
16. Oduwole OO, Li Y, Isomaa VV, Mantyniemi A, Pulkka AE, Soini Y & Vihko PT 2004 17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Research 64 7604-7609.
17. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL & Leitman DC 2004 Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Research 64 423-428.
18. Pasqualini J 2004 The selective estrogen enzyme modulators in breast cancer: a review. Biochimica et Biophysica Acta 1654 123-143.
19. Peltoketo H, Nokelainen P, Piao YS, Vihko R & Vihko P 1999 Two 17beta-hydroxysteroid dehydrogenases (17HSDs) of estradiol biosynthesis: 17HSD type 1 and type 7. Journal of Steroid Biochemistry and Molecular Biology 69 431-439.
20. Poutanen M, Isomaa V, Kainulainen K & Vihko R 1990 Progestin induction of 17 beta-hydroxysteroid dehydrogenase enzyme protein in the T-47D human breast-cancer cell line. International Journal of Cancer 46 897-901.
21. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P & Rochefort H 2001 Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Research 61 2537-2541.
22. Shaw JA, Udokang K, Mosquera JM, Chauhan H, Jones JL & Walker RA 2002 Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. Journal of Pathology 198 450-457.
23. Speirs V, Green AR, Walton DS, Kerin MJ, Fox JN, Carleton PJ, Desai SB & Atkin SL 1998 Short-term primary culture of epithelial cells derived from human breast tumours. British Journal of Cancer 78 1421-1429.
24. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J & Gustafsson JA 2004 Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. PNAS 101 1566-1571.
25. Suzuki T, Miki Y, Nakata T, Shiotsu Y, Akinaga S, Inoue K, Ishida T, Kimura M, Moriya T & Sasano H 2003 Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma. Journal of Steroid Biochemistry and Molecular Biology 86 449-454.
26. Suzuki T, Moriya T, Ariga N, Kaneko C & Sasano H 2000 17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. British Journal of Cancer 82 518-523.
27. Vihko P, Isomaa V & Gosh D 2001 Structure and function of 17beta-hydroxysteroid dehydrogenase type 1 and type 2. Molecular and Cellular Endocrinology 171 71-76.
28. Vindelöv LL, Christensen IJ & Nissen NI 1983 A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3 323-327.